Cempra presents new data on anti-microbials

Cempra Pharmaceuticals gave poster presentations last week on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102 (TAKSTA), the company's proprietary front-loading oral dosing regimen of sodium fusidate. The presentations were made at the 20th European Congress of Clinical Microbiology and Infectious Disease in Vienna, Austria.

CEM-101 has shown a broad spectrum of activity and high potency against respiratory and other serious pathogens in both in vitro and in vivo studies. The results from the first Phase I dose escalation study demonstrated that doses of CEM-101 from 200 to 600 mg were safe and well tolerated in healthy subjects and that the compound's pharmacokinetic profile is supportive of once-daily dosing.

Despite being available for over 40 years in Europe, sodium sodium fusidate (TAKSTA, CEM-102) demonstrated sustained activity against S. aureus including methicillin-resistant strains indicating that the compound is not highly susceptible to resistance development.

- read this Cempra release for more

Related Articles:
Cempra Pharmaceuticals - Top 20 Biotech VC Deals of 2009
Cempra rounds up $46M for antibiotic work

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.